The first oral proteasome inhibitor in the treatment of relapsed/refractory multiple myeloma
Authors:
H. Plonková; T. Jelínek; L. Szeligová; R. Hájek
Authors‘ workplace:
Lékařská fakulta, Ostravská univerzita, Ostrava
; Klinika hematoonkologie, Fakultní nemocnice Ostrava
Published in:
Transfuze Hematol. dnes,23, 2017, No. 4, p. 199-209.
Category:
Overview
Ixazomib is the first and only oral proteasome inhibitor, indicated for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone in patients who have received at least one prior therapy. The approval is based on the results of the randomized, double-blind, placebo-controlled phase III TOURMALINE-MM1 trial that demonstrated statistically significant improvement in progression-free survival in patients treated with the all-oral triplet combination of ixazomib plus lenalidomide and dexamethasone compared to patients in the lenalidomide and dexamethasone arm (20.6 months vs 14.7 months in the control group; hazard ratio 0.74; p = 0.01; median follow-up 14.7 months). The addition of ixazomib to a regimen of lenalidomide and dexamethasone is generally well tolerated with no negative impact on patient-reported quality of life. In this review, we highlight the efficacy, safety, pharmacokinetics and patient-reported quality of life data of ixazomib. We focus on the role of ixazomib in the treatment of patients with relapsed/refractory multiple myeloma including patients with high-risk cytogenetic features as well as heavily pretreated patients.
Key words:
ixazomib – proteasome inhibitor – multiple myeloma
Sources
1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364: 1046–1060.
2. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet 2015;385: 2197–2208.
3. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res 2011;17: 1225–1233.
4. Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374: 1621–1634.
5. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28: 1122–1128.
6. Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015;12: 42–54.
7. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMIDs and bortezomib: a multicenter International Myeloma Working Group study. Leukemia 2012;26: 149–157.
8. Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013;121: 884–892.
9. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127: 2955–2962
10. Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125: 2068–2074.
11. Dimopoulos MA, Delimpasi S, Katodritou E, et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014;25: 195–200.
12. Greipp PR, San MJ, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23: 3412–3420.
13. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012;120: 9–19.
14. Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamehasone in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 2015;126: 25.
15. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood 2016;127: 2569–2574.
16. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372: 142–152.
17. Dimopoulos M, Oriol A, Nahi H, et al. An open-label, randomised, phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRD) versus lenalidomide and dexamethasone (RD) in relapsed or refractory multiple myeloma (RRMM): POLLUX [abstract]. Haematologica 2016;101: 342.
18. Palumbo A, Chanan-Khan AA, Weisel K, et al. Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM): CASTOR study [abstract]. J Clin Oncol 2016;34: LBA4.
19. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366: 1782–1791.
20. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012;366: 1770–1781.
21. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012;119: 940–948.
22. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26: 595–608.
23. Amgen. KYPROLIS® (carfilzomib) for injection, for intravenous use. Prescribing information, 2016. http://pi.amgen.com/united_states/kyprolis/kyprolis_pi.pdf. 2016.
24. Romanus D, Raju A, Yong C, et al. Duration of therapy in U.S. pa-tients treated for relapsed/refractory multiple myeloma (RRMM) in the real-world [abstract]. Haematologica 2016;101(S1): E1301.
25. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015;373: 621–631.
26. San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014;15: 1195–1206.
27. Jelínek T, Všianská P, Hájek R. Monoklonální protilátky v léčbě mnohočetného myelomu. Transfuze Hematol. dnes 2015;21: 74–83.
28. Kubiczková L, Matějíková J, Sedlaříková L, et al. Inhibitory proteazomu v léčbě mnohočetného myelomu. Klin Onkol 2013;26: 11–18.
29. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010;70: 1970–1980.
30. Takeda Pharmaceuticals Limited. NINLARO® (ixazomib) capsules, for oral use. Prescribing information, 2015. Dostupné na www: https://www.ninlarohcp.com/prescribing-information.pdf . 2015.
31. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014;124: 1047–1055.
32. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 2014;124: 1038–1046.
33. Gupta N, Zhao Y, Hui AM, et al. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. Br J Clin Pharmacol 2015;79: 789–800.
34. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15: 1503–1512.
35. Gupta N, Hanley MJ, Harvey RD, et al. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol 2016;174: 748–759.
36. Gupta N, Hanley MJ, Venkatakrishnan K, et al. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol 2016;82: 728–738.
37. Richardson P, Hofmeister C, Rosenbaum C, et al. Twice-weekly ixazomib plus lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up data for patients who did not undergo stem cell transplantation (SCT) [abstract]. Haematologica 2017;102(S2): S780.
38. Richardson PG, Hofmeister CC, Rosenbaum CA, et al. Twice-weekly oral MLN9708 (ixazomib citrate), an investigational proteasome inhibitor, in combination with lenalidomide (len) and dexamethasone (dex) in patients (pts) with newly diagnosed multiple myeloma (MM): final phase 1 results and phase 2 data [abstract]. Blood 2013;122: 535.
39. Dimopoulos MA, Grosicki S, Jedrzejczak WW, et al. Randomized phase 2 study of the all-oral combination of investigational proteasome inhibitor (PI) ixazomib plus cyclophosphamide and low-dose dexamethasone (ICd) in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible (NCT02046070) [abstract]. Blood 2015;126: 26.
40. Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in pa-tients with relapsed multiple myeloma not refractory to bortezomib [abstract]. Blood Cancer J 2015;5: e338.
41. Kumar SK, LaPlant B, Reeder CB, et al. Randomized phase 2 trial of two different doses of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib [abstract]. Blood 2015;126: 3050.
42. Avet-Loiseau H, Bahlis N, Chng WJ, et al. Impact of cytogenetic risk status on efficacy and safety of ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in relapsed/refractory multiple myeloma patients in the global TOURMALINE-MM1 study [abstract]. Haematologica 2016;101(S1): 80.
43. Mateos MV, Masszi T, Grzasko N, et al. Efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in relapsed/refractory multiple myeloma patients: impact of prior therapy in the phase 3 TOURMALINE-MM1 study [abstract]. Haematologica 2016;101(S1): 527.
44. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359: 906–917.
45. Krishnan AY, Kapoor P, Palmer J, et al. A phase I/II study of ixazomib, pomalidomide, dexamethasone in relapsed refractory multiple myeloma: initial results [abstract]. J Clin Oncol 2016;34: 8008.
46. Reu FJ, Valent J, Malek E, et al. A phase I study of ixazomib in combination with panobinostat and dexamethasone in patients with relapsed or refractory multiple myeloma [abstract]. Blood 2015;126: 4221.
47. Voorhees P, Mulkey F, Hassoun H, et al. Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: phase I results [abstract]. Blood 2015;126: 375.
48. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica 2015;100: e207–e210.
49. Harvey RD. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. Clin Pharmacol 2014;6: 87–96.
50. Gupta N, Huh Y, Hutmacher MM, et al. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemother Pharmacol 2015;76: 507–516.
51. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85: 365–376.
52. Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43: 1670–1678.
53. Battisti WP, Wager E, Baltzer L, et al. Good publication practice for communicating company sponsored medical research: GPP3. Ann Intern Med 2015: 461–464.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2017 Issue 4
Most read in this issue
- Angioimmunoblastic T-lymphoma: overview, single centre experience and case report of the sequential development of difuse large B-cell lymphoma
- Next generation sequencing in acute myeloid leukaemia: new insights into the pathogenesis and development of leukemic clones
- Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission
- The first oral proteasome inhibitor in the treatment of relapsed/refractory multiple myeloma